Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596476 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A2CHRNA7TAAR1HTR2C | |
| SCHEMBL1333921 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A2CHRNA7TAAR1HTR2C | |
| SCHEMBL1335194 | 0.81 | MEN1 (0.38) | HTR2CHTR2BKMT2A | |
| SCHEMBL1335109 | 0.81 | MEN1 (0.38) | HTR2CHTR2BKMT2A | |
| SCHEMBL27742413 | 0.81 | HTR2B (0.35) | SLC6A3SLC6A2HTR2CHTR2AHTR2B | |
| SCHEMBL28782592 | 0.78 | SLC6A3 (0.47) | SLC6A3SLC6A2HTR2CSMN1; SMN2HTR2A | |
| SCHEMBL25478453 | 0.78 | PRCP (0.31) | SLC6A3SLC6A2HTR2B | |
| SCHEMBL1334966 | 0.78 | HTR2C (0.43) | HTR2CHTR2AHTR2BKMT2AMAPT | |
| SCHEMBL1334965 | 0.78 | HTR2C (0.43) | HTR2CHTR2AHTR2BKMT2AMAPT | |
| SCHEMBL1334838 | 0.76 | SLC6A2 (0.47) | SLC6A3SLC6A2CHRNA7SMN1; SMN2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569310-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141848-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | REN, MC2R, NR3C2 | SLC6A3 1447/4885SLC6A2 966/4885CHRNA7 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.